AgomAb Therapeutics N.V. American Depositary Shares Net Tangible Assets

AgomAb Therapeutics N.V. American Depositary Shares (AGMB) currently reports a net tangible assets of $130M as of December 2025. That compares with $190M in the prior-year period — down 30.4% year over year. Use the charts on this page to explore AgomAb Therapeutics N.V. American Depositary Shares's net tangible assets history and peer comparisons.

AgomAb Therapeutics N.V. American Depositary Shares's net tangible assets decreased from $190M to $130M — a 30.4% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AgomAb Therapeutics N.V. American Depositary Shares reported $130M in net tangible assets as of December 2025. That compares with $190M in the prior-year period — down 30.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $130M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for AgomAb Therapeutics N.V. American Depositary Shares, and consider following AGMB for alerts when major investors trade the stock.

AgomAb Therapeutics N.V. American Depositary Shares is classified in the Healthcare sector. On net tangible assets, it currently shows $130M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AGMB with unrelated industries.